Drugs / RK-4
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07166380 | Sep 2025 → Feb 2026 overdue | cerebral infarction | Neurodawn Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07203521 | Nov 2025 → Apr 2026 overdue | cerebral infarction, isolated bone marrow mastocytosis | Fuzhou Neurodawn Rongkang Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RK-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07203521 ↗ |
| Route | Other | “by transcranial bone marrow injection” NCT07166380 ↗ |